ACTG 244--CONDON 215 MUTATION IN ZVD MONOTHERAPY/MAINTENANCE THERPY

ACTG 244--ZVD 单一疗法/维持疗法中的 CONDON 215 突变

• 批准号: 6244461
• 负责人: Harvey Michael Friedman
• 金额: $ 2.36万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-03-17 至 1998-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6244461
• 关键词: AIDS; AIDS therapy; CD4 molecule; DNA damage; blood cell count; clinical research; clinical trials; human subject; human therapy evaluation; nucleic acid sequence; outcomes research; reverse transcriptase inhibitors; virus cytopathogenic effect; zidovudine

To validate that alteration in codon 215 of reverse transcriptase in plasma virus precedes the increase in circulating viral burden and the decline in CD4 count which have been observed in association with clinical failure on AZT. To determine whether alternative regimens of antiretroviral agents alter the course of unculating viral burden and CD4 changes when initiated on the basis of a mutation in codon 215.

为了验证逆转录酶215密码子的改变， 血浆病毒先于循环病毒负荷增加， CD4计数下降，这与临床 AZT失败 为了确定是否有替代方案， 抗逆转录病毒药物改变了病毒负荷和CD4 + T细胞亚群的进程， 当基于密码子215中的突变启动时发生变化。